MX2022002548A - Composiciones medicinales estables de cannabidiol. - Google Patents

Composiciones medicinales estables de cannabidiol.

Info

Publication number
MX2022002548A
MX2022002548A MX2022002548A MX2022002548A MX2022002548A MX 2022002548 A MX2022002548 A MX 2022002548A MX 2022002548 A MX2022002548 A MX 2022002548A MX 2022002548 A MX2022002548 A MX 2022002548A MX 2022002548 A MX2022002548 A MX 2022002548A
Authority
MX
Mexico
Prior art keywords
composition
cannabidiol
cbd
stable medicinal
antioxidant
Prior art date
Application number
MX2022002548A
Other languages
English (en)
Inventor
Anthony Ernest Bolton
Blagoja Ristevski
Original Assignee
Cardiol Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cardiol Therapeutics Inc filed Critical Cardiol Therapeutics Inc
Publication of MX2022002548A publication Critical patent/MX2022002548A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composición medicinal estable de cannabidiol para uso en administración oral, la composición que comprende cannabidiol (CBD) sintético que tiene una pureza de al menos 99.8%, preferentemente al menos 99.9%, junto con beta-cariofileno (BCP) que funciona tanto como un solvente como un antioxidante en las presentes composiciones. Las composiciones contienen además al menos un solvente lipófilo adicional (por ejemplo, triglicéridos de cadena media (MCT) y aceite de coco) y al menos un antioxidante adicional (por ejemplo, alfa tocoferol (vitamina E)). La composición está sustancialmente libre de otros cannabinoides, terpenos, solventes e ingredientes farmacéuticamente activos. También se divulgan métodos para elaborar y estabilizar CBD en una composición oral.
MX2022002548A 2019-09-09 2019-09-09 Composiciones medicinales estables de cannabidiol. MX2022002548A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CA2019/051259 WO2021046628A1 (en) 2019-09-09 2019-09-09 Stable medicinal cannabidiol compositions

Publications (1)

Publication Number Publication Date
MX2022002548A true MX2022002548A (es) 2022-03-22

Family

ID=74867096

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002548A MX2022002548A (es) 2019-09-09 2019-09-09 Composiciones medicinales estables de cannabidiol.

Country Status (8)

Country Link
US (1) US20220347118A1 (es)
EP (1) EP4028059A4 (es)
JP (1) JP7487292B2 (es)
AU (1) AU2019465548A1 (es)
BR (1) BR112022002409A2 (es)
CA (1) CA3152020C (es)
MX (1) MX2022002548A (es)
WO (1) WO2021046628A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4255494A1 (en) * 2020-12-07 2023-10-11 Cardiol Therapeutics Inc. Stable oral cannabidiol compositions
CN113480555B (zh) * 2021-08-11 2022-10-18 西北农林科技大学 一种含3,7-二氧杂双环[3,3,0]辛烷结构的木脂素类化合物及其制备方法和应用
TW202327557A (zh) * 2021-09-14 2023-07-16 日商三生醫藥股份有限公司 含丁香烴之組合物
WO2024079542A1 (en) * 2022-10-12 2024-04-18 Leiutis Pharmaceuticals Llp Novel liquid oral formulations of cannabidiol

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015184127A2 (en) * 2014-05-29 2015-12-03 Insys Pharma, Inc. Stable cannabinoid formulations
US20170266153A1 (en) * 2015-02-27 2017-09-21 Ebbu, LLC Compositions purposefully selected comprising purified cannabinoids and/or purified terpenes
CA2982250A1 (en) * 2015-03-19 2016-09-22 One World Cannabis Ltd. Preparations of cannabis emulsions and methods thereof
WO2016191651A1 (en) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations
BR102015024165A2 (pt) * 2015-09-18 2017-03-28 Prati Donaduzzi & Cia Ltda composição farmacêutica oral compreendendo canabinóide, processo para sua preparação e seu uso
US20190070124A1 (en) * 2016-03-04 2019-03-07 Sharon Anavi-Goffer Compositions of cb2 receptor selective agonists for treatment of mental disorders
IL246790A0 (en) * 2016-07-14 2016-09-29 Friedman Doron Self-dissolving compounds of cannabinoids
EP3615079A4 (en) * 2017-04-27 2020-09-23 Fresh Cut Development, LLC STABLE CANNABINOID FORMULATIONS
CA3065167A1 (en) * 2017-05-31 2018-12-06 Phytecs, Inc. Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use
CA3080434A1 (en) * 2017-10-30 2019-05-09 Endocanna Health, Inc. Graphical user interfaces for determining personalized endocannabinoid genotypes and associated recommendations

Also Published As

Publication number Publication date
EP4028059A1 (en) 2022-07-20
CA3152020C (en) 2024-03-26
JP7487292B2 (ja) 2024-05-20
US20220347118A1 (en) 2022-11-03
CA3152020A1 (en) 2021-03-18
BR112022002409A2 (pt) 2022-04-26
AU2019465548A1 (en) 2022-03-03
JP2022552056A (ja) 2022-12-15
WO2021046628A1 (en) 2021-03-18
EP4028059A4 (en) 2023-05-24

Similar Documents

Publication Publication Date Title
MX2022002548A (es) Composiciones medicinales estables de cannabidiol.
MX2018014978A (es) Composiciones nasales de cannabidiol.
PE20071067A1 (es) Composiciones de rapamicina y cci-779 y metodo para su preparacion
CO5580835A2 (es) Nuevas formulaciones analogas de ciclosporina
KR102487299B1 (ko) 안정화된 오메가-3 안과용 조성물
WO2002067864A3 (en) Coenzyme q products exhibiting high dissolution qualities
RU2011119796A (ru) Фармацевтические системы доставки для гидрофобных лекарственных средств и композиций, их содержащих
DE102010050570A1 (de) Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors
CA2589993A1 (en) Room-temperature stable dronabinol formulations
SG11201906708WA (en) Stable and liposoluble active ingredient composition, microcapsule, and preparation method and application thereof
RU2013100984A (ru) Офтальмологические композиции для введения активных жирорастворимых ингредиентов
WO2006032115A3 (en) Composition against cardiovascular diseases
ITMI20072051A1 (it) Composizione a base di pellet di acido lipoico
RU2007137182A (ru) Микроэмульсии соединений, связывающихся с каннабиноидными рецепторами
MX2021013285A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
TW201340961A (zh) 眼科用組成物
EP1680096B1 (en) New formulation for retinoid-containing soft gelatin capsules
DE602005007380D1 (de) Formulierung für die orale verabreichung mit gesundheitsfördernder wirkung auf das herz-kreislauf-system
CO4790151A1 (es) COMPOSICIONES QUE COMPRENDEN UN INHIBIDOR DE LA PROTEASA DEL VIH COMO VX478 Y UN COMPUESTO DE VITAMINA E sOLUBLE EN AGUA COMO VITAMINA E - TPGS
AR045996A1 (es) Formulaciones semi-solidas para la administracion oral de taxoides
PE20220942A1 (es) COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMO
JP2007169232A (ja) 眼科用組成物
TWI796396B (zh) 水性眼科用組成物及乳液粒子的微粒化方法
AR045912A1 (es) Composiciones farmaceuticas que contienen derivados de azetidina
KR102453524B1 (ko) 안과용 조성물 및 그 제조 방법